Myelodysplastic syndrome, or MDS, is a group of blood disorders where the bone marrow doesn't produce enough healthy blood cells. Instead of making normal red blood cells, white blood cells, and platelets, the marrow produces defective, immature cells that don't function properly.
MDS isn't a single disease but rather a collection of related conditions that all share this core problem. Think of it like a factory where the assembly line keeps producing faulty products; the raw materials go in, but what comes out doesn't work as intended.
And in India, where routine blood testing isn't always standard, many patients don't discover they have MDS until complications like persistent anemia or infections prompt a deeper workup.
Dysfunction in Blood Cell Production
The bone marrow produces blood cells that are abnormally shaped or don't mature properly. These defective cells die either in the marrow itself or shortly after entering the bloodstream. The result is a shortage of healthy cells circulating in the body, which leads to anemia, infections, and bleeding problems.
Accumulation of Immature Cells (Blasts)
In some MDS types, immature cells called blasts build up in the bone marrow. Put simply, when blast counts rise above a certain threshold, MDS begins to look and behave more like acute myeloid leukemia (AML). That's why monitoring blast percentages is a key part of MDS management.
Adults over 60 face the highest risk, and MDS is more common in men than women. First, age-related changes in bone marrow function play a role. Second, prior exposure to chemotherapy or radiation for other cancers can trigger secondary MDS years later.
What many doctors won't say outright is that many MDS cases in India go undiagnosed because the symptoms, particularly fatigue, get attributed to aging or nutritional deficiency rather than a bone marrow disorder.
Not all MDS behaves the same way. The type determines how quickly the disease may progress and what treatment approach fits best:
MDS doesn't use the standard stages 1 through 4 system, or rather, doctors use scoring systems that assess risk based on blast counts, chromosome changes, and how low blood counts have dropped. It's a bit like assigning a risk grade rather than a stage number:
Symptoms come from having too few healthy blood cells. In most cases, though not all, fatigue and weakness are the first things patients notice. Roughly speaking, MDS symptoms tend to develop slowly and worsen gradually:
The exact cause of myelodysplasia isn't always identifiable, but several factors raise the risk. It's like a combination lock where multiple pieces need to align:
If fatigue, frequent infections, or unexplained bruising persist beyond two to three weeks, it's time to see a specialist.
And if routine blood tests show consistently low counts in any blood cell type, that warrants further investigation rather than a wait-and-watch approach. The honest answer is that a simple complete blood count (CBC) can flag MDS-related changes early.
Catching MDS early gives doctors more room to manage the disease before it progresses. Think of it as getting ahead of a problem before it compounds:
An MDS diagnosis of myelodysplastic syndrome doesn't come from a single test. First, blood tests reveal low cell counts or abnormal cell shapes. Second, bone marrow biopsy confirms the diagnosis and classifies the type.
Third, cytogenetic analysis identifies chromosome changes that shape treatment decisions. Think of each test as peeling back another layer of the puzzle.
Treatment depends on the MDS type, risk score, age, and overall health. Well, almost always the first question is whether the patient is a candidate for a stem cell transplant, because that's currently the only potentially curative option.
But many patients aren't candidates for transplant due to age or other health conditions, and they benefit from supportive care and disease-modifying treatments:
Hematologists and oncologists at HCG Cancer Hospital in Bengaluru, Mumbai, Ahmedabad, and Kolkata handle MDS from initial blood workup through treatment and long-term monitoring. The honest answer is that MDS management requires specialized hematology expertise, and HCG Cancer Hospital's multi-disciplinary approach means hematologists, pathologists, and transplant specialists review each case together.
But even patients who aren't transplant candidates get structured supportive care and regular monitoring plans.
There's no guaranteed way to prevent MDS, but reducing exposure to known risk factors helps. Think of it as stacking the odds in your favor rather than eliminating risk:
MDS is a complex group of blood disorders that requires specialized care. Actually, the difference between catching it early and catching it late can change the entire treatment approach and quality of life. Patients who notice persistent fatigue, frequent infections, or unusual bruising should seek evaluation promptly rather than attributing symptoms to aging alone.
Feel free to reach out to us.
